DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20194662

A comparative study of effectiveness of autologus serum therapy with oral antihistamines versus oral methotrexate and oral antihistamines in chronic urticaria patients

Amit Kumar Pandey, Suryakant Ojha, Aayushi Mohan, Sunil Prajapati

Abstract


Background: Chronic urticaria (CU) is a worrisome problem and patients of CU suffer from the morbidity that arises from irritable itch thus they are subjected to a huge antihistamine pill burden. The symptoms are more prominent in autoreactive urticaria (AU) where auto-antibodies in blood causing recurrent flares. Therefore a need of adjunctive drug to reduce the pill burden is felt need.

Methods: A randomized, controlled study was done. 50 patients were given AST and 50 patients were given oral pulse methotrexate (10-15 mg once weekly) along with levocetrizine in an on-demand basis in both groups. AST was given weekly for nine weeks and followed-up for a total period of 24 weeks. Urticaria total severity score (UTSS) was used to evaluate the effectiveness of treatment. Safety parameters assessed were the spontaneously reported adverse events and laboratory parameters.

Results: UTSS showed significant improvement from baseline, 7th week and 8th week onwards in AST group and methotrexate group respectively. Group comparison showed significant improvement 4th week onwards.

Conclusions: Autologous serum therapy as well as methotrexate both proved effective in chronic urticaria patients. On follow-up improvement is sustained for at least 3-4 months after the last injection in case of AST. 


Keywords


Urticaria, Methotrexate, AST

Full Text:

PDF

References


Black AK, Grattan CEH. Urticaria. In: Burns DA, Breathnach SM, Cox NH, Griffiths CEM, editors. Rooks Textbook of Dermatology. 8th ed. Blackwell Publishing Ltd; 2010: 22.1-22.39.

O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201.

Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66(3):317-30.

Gaig P, Olona M, Munoz Lejarazu D, Caballero MT, Dominguez FJ, Echechipia S, et al. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol. 2004;14(3):214-20.

Lapi F, Cassano N, Pegoraro V, Cataldo N, Heiman F, Cricelli I, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. Br J Dermatol. 2016;174(5):996-1004.

Greaves MW. Chronic urticaria. N Engl J Med 1995;332:1767-72.

Maurer M, Weller K, Bindslev-Jensen C, Gime×nez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317-30.

Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: A study of 90 patients. J Allergy Clin Immunol. 1989;84:66-71.

Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2015;45(3):547-65.

Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy. 2009;64(10):1427-43.

Ortonne JP. Chronic urticaria: a comparison of management guidelines. Expert Opin Pharmacother. 2011;12(17):2683-93.

Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev. 2012;(3):CD008596.

Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-7.

Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-87.

Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med. 1995;26(5):547-51.

de Silva NL, Damayanthi H, Rajapakse AC, Rodrigo C, Rajapakse S. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10(1):24.

Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence-based review, part 2. Ann Allergy Asthma Immunol. 2008;100(6):517-26.

Mitchell S, Balp MM, Samuel M, McBride D, Maurer M. Systematic review of treatments for chronic spontaneous urticaria with inadequate response to licensed first-line treatments. Int J Dermatol. 2015;54(9):1088-104.

Zuberbier T, Asero R, Bindslev-Jensen C, Canonica GW, Church MK, Gime´nez-Arnau AM, et al. EAACI/GALEN/EDF/WAO guideline: Definition, classification and diagnosis of urticaria. Allergy. 2009;64:1417-26.

Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: A cost analysis of 50 nonimmuno suppressed patients. Arch Dermatol. 2008;144:35-9.

Perez A, Woods A, Grattan CE. Methotrexate: A useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol. 2010;162:191-4.

Okubo Y, Shigoka Y, Yamazaki M, Tsuboi R. Double dose of cetirizine hydrochloride is effective for patients with urticaria resistant: A prospective, randomized, non-blinded, comparative clinical study and assessment of quality of life. J Dermatol Treat. 2013;24:153-60.

Zuberbier T, Asero R, Bindslev-Jansen C, Canonica GW, Church MK, Giminez-Arnau AM, et al. EAACI/GALEN/EDF/WAO guideline: Management of urticaria. Allergy. 2009;64:1427-43.

Sagi L, Solomon M, Baum S, Lyakhovitsky A, Trau H, Barzilai A. Evidence for methotrexate as a useful treatment for steroid-dependant chronic urticaria. Acta Derm Venereol. 2011;91:303-6.

Bocci V. Autohaemotherapy after treatment of blood with ozone. A reappraisal. J Int Med Res. 1994;22:131-44.

Pittler MH, Armstrong NC, Cox A, Collier PM, Hart A, Ernst E. Randomized, double-blind, placebo-controlled trial of autologous blood therapy for atopic dermatitis. Br J Dermatol. 2003;148:307-13.

Birnbaum G, Weksler ME, Siskind GW. Demonstration of an antibody-mediated tolerance state and its effect on antibody affinity. J Exp Med. 1975;141:411-26.

Yang X. Does allergen immunotherapy alter the natural course of allergic disorders? Drugs. 2001;61:365-74.

Bajaj AK, Saraswat A, Upadhyay A, Damisetty R, Dhar S. Autologous serum therapy in chronic urticaria: Old wine in a new bottle. Indian J Dermatol Venereol Leprol. 2008;74:109-13.

Kocatürk E, Aktaş S, Türkoǧlu Z, Kavala M, Zindanci I, Koc M, et al. Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: A placebo controlled, randomized, single-blind study. J Dermatolog Treat. 2012;23:465-71.